ISSAQUAH, Wash. - December 1, 2020 - (Newswire.com)
CaaMTech, Inc., announced today that the company has entered into a collaborative research agreement with the Leibniz Institute for Natural Product Research and Infection Biology to research psychedelic mushroom compositions. The Leibniz Institute for Natural Product Research and Infection Biology (also known as the Hans Knöll Institute [HKI] after its founder) is located in Jena, Germany. Famed mycologist Prof. Dr. Dirk Hoffmeister, head of the Research Group Pharmaceutical Microbiology, will lead the research on behalf of HKI.
The collaborative research aims to fill several gaps in the scientific understanding of the chemical composition of psychedelic psilocybin-containing mushrooms, colloquially known as "magic mushrooms." Magic mushrooms (and their most well known psychedelic compound, psilocybin) have undergone a wave of new research in the past several years. More recently, magic mushrooms have been decriminalized in several US jurisdictions and Oregon voters overwhelmingly moved to legalize psychotherapy utilizing these fungi in a November ballot measure.
"Psilocybin is just one of many tryptamines found in magic mushrooms and probably not the one with the most potential or the most important effects," said Dr. Andrew Chadeayne, CEO of CaaMTech. "Understanding the chemical composition of magic mushrooms allows us to quantifiably distinguish their effects from pure psilocybin and harness the advantages."
The research, conducted by Dr. Hoffmeister's team at HKI will, among other work, examine the chemical variability within and between magic mushroom strains.
"Metabolic profiling of these fungi is an exciting endeavor," said Dr. Hoffmeister. "A more global view on their metabolic diversity has surprisingly not been undertaken yet, but is needed to help us understand their effects more profoundly. From an academic perspective, it may also tell us why nature has evolved these compounds."
About CaaMTech
CaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.
Media Contact
Davis Wuolle
davis@caam.tech
+1.510.747.9001
Press Release Service by Newswire.com
Original Source: CaaMTech Collaborates With the Leibniz Institute for Natural Product Research to Investigate Psychedelic Mushrooms
